日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Plain language summary of publication to understand the ROSALIA study: a new biosimilar denosumab for bone health

用通俗易懂的语言总结 ROSALIA 研究：一种用于骨骼健康的新型生物类似药地诺单抗

期刊:Therapeutic Advances in Musculoskeletal Disease
影响因子:4.1
doi:10.1177/1759720X251335147
Eastell, Richard; Jeka, Sławomir; Lustberg, Maryam; Edgerton, Colin; Żuchowski, Paweł; Vogg, Barbara
发表日期：2025
文献求助 收藏

Cognitive Impairment in Rheumatoid Arthritis: The Role of Pain, Inflammation, and Multimorbidity in Neuropsychological Outcomes

类风湿性关节炎的认知障碍：疼痛、炎症和多种疾病在神经心理学结果中的作用

期刊:Biomedicines
影响因子:3.9
doi:10.3390/biomedicines13071699
Pigłowska-Juhnke, Agnieszka; Stanisławska-Kubiak, Maia; Kalmus, Piotr; Waszczak-Jeka, Marzena; Samborski, Włodzimierz; Mojs, Ewa
炎症
炎症/感染
Immunology/Inflammation
神经科学
关节炎
发表日期：2025
文献求助 收藏

Prognostic value of trabecular bone score for major osteoporotic fractures in patients with radiographic axial spondyloarthritis: a 3-year prospective cohort study

骨小梁评分对放射学诊断为中轴型脊柱关节炎患者发生主要骨质疏松性骨折的预后价值：一项为期3年的前瞻性队列研究

期刊:Rheumatology International
影响因子:2.9
doi:10.1007/s00296-025-06026-8
Żuchowski, Paweł; Dura, Marta; Jeka, Daniel; Gajewicz-Sawicka, Katarzyna; Kułakowski, Michał; Muche, Burkhard
代谢
关节炎
骨折
骨质疏松
发表日期：2025
文献求助 收藏

Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis

生物类似药 CT-P47 与参考药物托珠单抗的疗效和安全性：一项针对类风湿性关节炎患者的随机、活性对照、双盲 III 期研究的 1 年结果

期刊:Clinical Drug Investigation
影响因子:2.7
doi:10.1007/s40261-025-01453-8
Burmester, Gerd; Trefler, Jakub; Racewicz, Artur; Jaworski, Janusz; Zielińska, Agnieszka; Krogulec, Marek; Jeka, Sławomir; Wojciechowski, Rafał; Kolossa, Katarzyna; Dudek, Anna; Krajewska-Włodarczyk, Magdalena; Hrycaj, Paweł; Klimiuk, Piotr Adrian; Kim, SungHyun; Suh, JeeHye; Yang, GoEun; Kim, YunAh; Jung, YooBin; Park, GaHee; Smolen, Josef S
关节炎
发表日期：2025
文献求助 收藏

Assessing real-world treatment with SDZ ETN (an etanercept biosimilar) in people with rheumatic diseases included in the COMPACT study: a plain language summary

COMPACT 研究纳入的风湿性疾病患者使用 SDZ ETN（依那西普生物类似药）进行真实世界治疗的评估：简明语言摘要

期刊:Immunotherapy
影响因子:2.3
doi:10.1080/1750743X.2025.2493039
Schmalzing, Marc; Kellner, Herbert; Askari, Ayman; de Toro Santos, Javier; Perez-Coleman, Julio Cesar Vazquez; Foti, Rosario; Jeka, Sławomir; Allanore, Yannick; Peichl, Peter; Oehri, Martin; Betteridge, Neil; Salvati, Cristofer; Romero, Elisa; Brueckmann, Ines; Sheeran, Tom
OMP
COMP
OMPA
发表日期：2025
文献求助 收藏

Stochastic resonance stimulation effect on stability during walking in people with Parkinson disease

随机共振刺激对帕金森病患者行走稳定性的影响

期刊:
影响因子:
doi:10.1080/23335432.2025.2584665
Alsaqabi, Eman; DiBianca, Stephen; Sansare, Ashwini; Verma, Khushboo; Reimann, Hendrik; Jeka, John
帕金森
神经科学
发表日期：2025
文献求助 收藏

Environmental and Genetic Determinants of Ankylosing Spondylitis

强直性脊柱炎的环境和遗传决定因素

期刊:International Journal of Molecular Sciences
影响因子:4.9
doi:10.3390/ijms25147814
Bilski, Rafał; Kamiński, Piotr; Kupczyk, Daria; Jeka, Sławomir; Baszyński, Jędrzej; Tkaczenko, Halina; Kurhaluk, Natalia
强直性脊柱炎
免疫/内分泌
发表日期：2024
文献求助 收藏

Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47

CT-P47 与参考药物托珠单抗的疗效和安全性：一项针对类风湿性关节炎患者的随机、活性对照、双盲 III 期研究的 32 周结果，包括从参考药物托珠单抗转换为 CT-P47 的 8 周数据

期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2024-004514
Smolen, Josef S; Trefler, Jakub; Racewicz, Artur; Jaworski, Janusz; Zielińska, Agnieszka; Krogulec, Marek; Jeka, Sławomir; Wojciechowski, Rafał; Kolossa, Katarzyna; Dudek, Anna; Krajewska-Włodarczyk, Magdalena; Hrycaj, Paweł; Klimiuk, Piotr Adrian; Burmester, Gerd R; Kim, SungHyun; Bae, YunJu; Yang, GoEun; Jung, YooBin; Hong, JiWoo; Keystone, Edward
关节炎
发表日期：2024
文献求助 收藏

A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48)

一项 3 期随机、双盲、活性对照临床试验，比较托珠单抗生物类似药 BAT1806/BIIB800 与托珠单抗参考产品在对甲氨蝶呤反应不足的中重度类风湿性关节炎患者中的疗效：治疗期 2 分析（第 24 周至第 48 周）

期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-024-03375-w
Leng, Xiaomei; Leszczyński, Piotr; Jeka, Slawomir; Liu, Shengyun; Liu, Huaxiang; Miakisz, Malgorzata; Gu, Jieruo; Kilasonia, Lali; Stanislavchuk, Mykola; Yang, Xiaolei; Zhou, Yinbo; Dong, Qingfeng; Mitroiu, Marian; Addison, Janet; Rezk, Mourad F; Zeng, Xiaofeng
关节炎
发表日期：2024
文献求助 收藏

Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study

SDZ ETN（一种依那西普生物类似药）在风湿病患者中的真实世界疗效和安全性：多国COMPACT研究的最终结果

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-023-02706-8
Schmalzing, Marc; Kellner, Herbert; Askari, Ayman; De Toro Santos, Javier; Vazquez Perez-Coleman, Julio Cesar; Foti, Rosario; Jeka, Sławomir; Haraoui, Boulos; Allanore, Yannick; Peichl, Peter; Oehri, Martin; Rahman, Masiur; Furlan, Fabricio; Romero, Elisa; Hachaichi, Sohaib; Both, Charlotte; Brueckmann, Ines; Sheeran, Tom
OMP
COMP
OMPA
发表日期：2024
文献求助 收藏